IL179240A - Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody - Google Patents
Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibodyInfo
- Publication number
- IL179240A IL179240A IL179240A IL17924006A IL179240A IL 179240 A IL179240 A IL 179240A IL 179240 A IL179240 A IL 179240A IL 17924006 A IL17924006 A IL 17924006A IL 179240 A IL179240 A IL 179240A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- allograft
- medicaments
- prolong
- survival
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57144404P | 2004-05-14 | 2004-05-14 | |
| PCT/US2005/017048 WO2005110481A2 (en) | 2004-05-14 | 2005-05-16 | Prolongation of survival of an allograft by inhibiting complement activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL179240A0 IL179240A0 (en) | 2007-03-08 |
| IL179240A true IL179240A (en) | 2014-07-31 |
Family
ID=35385551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL179240A IL179240A (en) | 2004-05-14 | 2006-11-13 | Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody |
| IL233326A IL233326A0 (en) | 2004-05-14 | 2014-06-23 | Extending the survival of donor tissue by inhibiting the activity of complement |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233326A IL233326A0 (en) | 2004-05-14 | 2014-06-23 | Extending the survival of donor tissue by inhibiting the activity of complement |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090028850A1 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2338511A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5161567B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005244012C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2566716C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1755674T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2528362T3 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1222342A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL179240A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ551308A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1755674T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1755674E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1755674T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005110481A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2338511A3 (en) | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| BRPI0708424A2 (pt) * | 2006-03-02 | 2011-05-31 | Alexion Pharma Inc | prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| JP6223659B2 (ja) * | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| US20110110953A1 (en) * | 2009-06-29 | 2011-05-12 | Dennis Keith Bishop | Compound and method for treatment of chronic transplant rejection |
| JP5871798B2 (ja) * | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| WO2011146395A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| EP3033093A1 (en) | 2013-08-16 | 2016-06-22 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| JP6479974B2 (ja) * | 2014-10-15 | 2019-03-06 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 大規模エクリズマブ産生細胞培養を再現する方法 |
| US20180311299A1 (en) * | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| AU2018383751B2 (en) | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| GB201911931D0 (en) * | 2019-08-20 | 2019-10-02 | Univ College Cardiff Consultants Ltd | Anti-C7 antibody or antibody fragment |
| US20210353685A1 (en) * | 2020-05-14 | 2021-11-18 | Brain Cancer Research Institute | Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways |
| CN114532982A (zh) * | 2022-01-12 | 2022-05-27 | 高谋 | 评价干细胞系统移植调控补体活化作用的体系 |
| CN120344253A (zh) * | 2022-12-08 | 2025-07-18 | 诺麦塔制药有限公司 | 延长移植物和受体存活期的组合物和方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2588579B2 (ja) | 1988-04-21 | 1997-03-05 | 株式会社クラレ | 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法 |
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| US5573940A (en) | 1989-06-12 | 1996-11-12 | Oklahoma Medical Research Foundation | Cells expressing high levels of CD59 |
| US20010018051A1 (en) * | 1990-04-09 | 2001-08-30 | White David James Graham | Inhibition of allograft and concordant xenograft rejection |
| GB9007971D0 (en) * | 1990-04-09 | 1990-06-06 | Imutran Ltd | Pharmaceutical formulations |
| CA2097825A1 (en) * | 1990-12-06 | 1992-06-07 | Henry C. Marsh, Jr. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5679345A (en) * | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6355242B1 (en) * | 1997-05-23 | 2002-03-12 | Ixion Biotechnology, Inc. | Materials and methods for treating or preventing oxalate-related disease |
| IL137614A0 (en) | 1998-02-04 | 2001-07-24 | Gen Hospital Corp | An inhibitor of a costimulatory pathway and hematopoietic stem cells for promoting graft acceptance |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| AU1521000A (en) | 1998-11-06 | 2000-05-29 | Schepens Eye Research Institute, Inc., The | Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| AUPQ431299A0 (en) | 1999-11-26 | 1999-12-23 | Unisearch Limited | Method of inducing immune tolerance |
| US6538028B1 (en) * | 2000-02-01 | 2003-03-25 | Vanderbilt University | Method for inhibiting complement activation |
| ATE449791T1 (de) * | 2000-10-10 | 2009-12-15 | Genentech Inc | Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung |
| ES2322442T3 (es) * | 2001-06-08 | 2009-06-22 | Novartis Ag | Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina. |
| MXPA04001301A (es) | 2001-08-17 | 2004-07-08 | Tanox Inc | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
| US20030180301A1 (en) * | 2002-01-22 | 2003-09-25 | Shaf Keshavjee | Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection |
| WO2005025509A2 (en) * | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| EP2338511A3 (en) | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| MXPA06013463A (es) * | 2004-05-17 | 2007-03-01 | Combinatorx Inc | Metodos y reactivos para el tratamiento de desordenes inmuno-inflamatorios. |
-
2005
- 2005-05-16 EP EP10012377A patent/EP2338511A3/en not_active Withdrawn
- 2005-05-16 SI SI200531936T patent/SI1755674T1/sl unknown
- 2005-05-16 JP JP2007513459A patent/JP5161567B2/ja not_active Expired - Lifetime
- 2005-05-16 PT PT57799249T patent/PT1755674E/pt unknown
- 2005-05-16 ES ES05779924.9T patent/ES2528362T3/es not_active Expired - Lifetime
- 2005-05-16 EP EP05779924.9A patent/EP1755674B1/en not_active Revoked
- 2005-05-16 PL PL05779924T patent/PL1755674T3/pl unknown
- 2005-05-16 EP EP14177646.8A patent/EP2815767A1/en not_active Withdrawn
- 2005-05-16 NZ NZ551308A patent/NZ551308A/en not_active IP Right Cessation
- 2005-05-16 AU AU2005244012A patent/AU2005244012C1/en not_active Ceased
- 2005-05-16 CA CA2566716A patent/CA2566716C/en not_active Expired - Fee Related
- 2005-05-16 WO PCT/US2005/017048 patent/WO2005110481A2/en not_active Ceased
- 2005-05-16 US US11/596,382 patent/US20090028850A1/en not_active Abandoned
- 2005-05-16 DK DK05779924.9T patent/DK1755674T3/en active
- 2005-05-16 EP EP16160321.2A patent/EP3056218A1/en not_active Withdrawn
-
2006
- 2006-11-13 IL IL179240A patent/IL179240A/en not_active IP Right Cessation
-
2007
- 2007-08-24 HK HK16110635.2A patent/HK1222342A1/en unknown
- 2007-08-24 HK HK15102461.9A patent/HK1201758A1/en unknown
-
2012
- 2012-11-08 JP JP2012246213A patent/JP5590624B2/ja not_active Expired - Lifetime
-
2014
- 2014-02-07 JP JP2014021907A patent/JP2014080438A/ja not_active Withdrawn
- 2014-06-23 IL IL233326A patent/IL233326A0/en unknown
-
2017
- 2017-03-31 US US15/476,644 patent/US20170267751A1/en not_active Abandoned
-
2018
- 2018-11-14 US US16/190,601 patent/US20190309053A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5161567B2 (ja) | 2013-03-13 |
| PL1755674T3 (pl) | 2015-05-29 |
| EP3056218A1 (en) | 2016-08-17 |
| IL233326A0 (en) | 2014-08-31 |
| ES2528362T3 (es) | 2015-02-09 |
| HK1201758A1 (en) | 2015-09-11 |
| EP2338511A2 (en) | 2011-06-29 |
| WO2005110481A3 (en) | 2006-06-22 |
| DK1755674T3 (en) | 2015-02-09 |
| HK1222342A1 (en) | 2017-06-30 |
| AU2005244012B2 (en) | 2011-08-18 |
| US20090028850A1 (en) | 2009-01-29 |
| AU2005244012C1 (en) | 2013-05-02 |
| SI1755674T1 (sl) | 2015-04-30 |
| AU2005244012A1 (en) | 2005-11-24 |
| IL179240A0 (en) | 2007-03-08 |
| EP1755674B1 (en) | 2014-11-19 |
| JP2007537299A (ja) | 2007-12-20 |
| WO2005110481A2 (en) | 2005-11-24 |
| US20190309053A1 (en) | 2019-10-10 |
| AU2005244012B9 (en) | 2011-11-03 |
| NZ551308A (en) | 2009-06-26 |
| JP2013032391A (ja) | 2013-02-14 |
| JP5590624B2 (ja) | 2014-09-17 |
| CA2566716C (en) | 2014-12-23 |
| EP1755674A2 (en) | 2007-02-28 |
| PT1755674E (pt) | 2015-02-05 |
| JP2014080438A (ja) | 2014-05-08 |
| HK1101962A1 (en) | 2007-11-02 |
| EP2338511A3 (en) | 2012-07-25 |
| CA2566716A1 (en) | 2005-11-24 |
| US20170267751A1 (en) | 2017-09-21 |
| EP2815767A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL186162A (en) | Spray drug containing amikacin and systems and devices for giving | |
| PT2985026T (pt) | Sistemas de distribuição farmacêuticos para fármacos hidrófobos e composições compreendendo os mesmos | |
| HUS1800034I1 (hu) | Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény | |
| IL199216A (en) | Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses | |
| IL191117A (en) | Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor | |
| IL196167A0 (en) | Bicyclic compounds and pharmaceutical compositions containing the same | |
| IL186671A (en) | Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs | |
| EP1973593A4 (en) | DEVICES FOR DISPENSING AND STORING MEDICAMENTS AND SYSTEMS COMPRISING THE SAME | |
| GB2402063B (en) | Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof | |
| IL188151A0 (en) | ANTIBODIES THAT BIND TO HUMAN PDGFRd AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| IL176749A0 (en) | ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| ZA200809998B (en) | Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same | |
| IL198578A0 (en) | Unit dosage package and methods for administering weight loss medications | |
| IL245365A0 (en) | ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses | |
| CL2007003855A1 (es) | Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t | |
| IL179835A0 (en) | Pharmaceutical compositions containing amphotericin b and delivery systems containing the same | |
| IL187224A0 (en) | Bicyclic derivatives and pharmaceutical compositions containing the same | |
| EP2220081A4 (en) | GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES | |
| IL190017A0 (en) | Bicyclic compounds and pharmaceutical compositions containing the same | |
| SI2066351T1 (sl) | Humana protitelesa, ki vežejo cxcr4 in njihova uporaba | |
| IL186854A0 (en) | Urea derivatives and pharmaceutical compositions containing the same | |
| BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
| ZA200701443B (en) | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle | |
| ZA200901212B (en) | Improvements of the biovailability of active substances having an amidine function in medicaments | |
| ZA200807348B (en) | Dosage aerosols for the administration of pharmaceutical preparations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |